Policy
In a Cabinet meeting, Health Secretary Robert F. Kennedy Jr. said the website could go live “probably in the next 10 days,” but an exact launch date remains unclear.
FEATURED STORIES
An inconsistent boom-and-bust cycle funding environment for early-stage biotech innovations and burdensome regulation threaten the U.S.’s half-century-long dominance in the biotech sector.
Acadia Pharma’s Catherine Owen Adams is one of the founders of a group of small- to mid-cap biotechs advocating against a ‘peanut butter blanket’ approach to drug pricing for small companies.
Former European Trade Commissioner Phil Hogan and former U.S. Senator Richard Burr, speaking on a panel at the J.P. Morgan Healthcare Conference, pushed to see a larger picture beyond the Trump administration’s year of chaos and confusion.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
New York-based Kallyope and Danish company Novo Nordisk A/S signed a research collaboration and option deal to discover novel therapeutics to treat obesity and diabetes.
Ortho Dermatologics, a division of Quebec-based Valeant Pharmaceuticals International, received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) for Duobrii for plaque psoriasis.
June is Alzheimer’s & Brain Awareness Month and June 21 is dubbed “The Longest Day,” which focuses on raising awareness of Alzheimer’s disease.
The U.S. Food and Drug Administration (FDA) placed a clinical hold on Boston-based Ziopharm Oncology’s Phase I trial of its Sleeping Beauty CAR-T therapy.
Shares of Solid Biosciences have jumped 11 percent in premarket trading after the company announced the U.S. Food and Drug Administration has lifted a clinical hold on the company’s Phase I/II clinical trial gene therapy treatment for Duchenne muscular dystrophy (DMD).
A former biotech analyst who was charged with insider trading last fall will spend four months in prison this fall after pleading guilty to one count of securities fraud.
If convicted Holmes and Balwani face a maximum sentence of 20 years in prison.
Epizyme Posts Positive Interim Data for Follicular Lymphoma Treatment, Despite Partial Clinical Hold
Despite some of the troubles Epizyme has seen with its lead drug candidate tazemetostat, including a partial clinical hold placed by the U.S. Food and Drug Administration, the company is pushing forward with positive interim data presented at the 23rd Congress of the European Hematology Association.
Shares of Motif Bio plc shot up late Thursday after the company announced it had completed its rolling submission of a New Drug Application to the U.S. Food and Drug Administration for its acute bacterial skin and skin structure infections (ABSSSI) treatment, iclaprim.
Days after President Donald Trump signed the Right-to-Try legislation there are still many uncertainties about the law.